Relay Therapeutics director granted 32,947 stock options

Relay Therapeutics director Claire Mazumdar received a new stock option grant.

Rhea-AI Filing Summary

Relay Therapeutics director Claire Mazumdar received a new stock option grant. The Form 4 reports an award of options covering 32,947 shares of Relay Therapeutics common stock at an exercise price of $14.09 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following that date and expire on June 8, 2036. After this grant, Mazumdar holds stock options for 32,947 underlying shares directly.

Insider Trade Summary

Grant/Award: 32,947 shares

Grant/Award 1 txn

Insider Mazumdar Claire

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,947	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 32,947 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Key Figures

Option grant size: 32,947 shares Exercise price: $14.09 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 32,947 shares Stock Option (Right to Buy) granted June 9, 2026

Exercise price $14.09 per share Conversion or exercise price of granted options

Expiration date June 8, 2036 Option expiration for 32,947-share grant

Underlying shares 32,947 shares Common stock underlying the stock option award

Post-grant option holdings 32,947 shares Total underlying shares following the reported transaction

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, underlying security, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

underlying security financial

"underlying_security_title: Common Stock; underlying_security_shares"

annual meeting of stockholders financial

"vests in full on the earlier to occur of ... or (b) the date of the next annual meeting of stockholders"

vests in full financial

"and vests in full on the earlier to occur of (a) the first anniversary"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Relay Therapeutics (RLAY) report for Claire Mazumdar?

Relay Therapeutics reported a stock option grant to director Claire Mazumdar. She received options for 32,947 shares of common stock as a compensation-related award, with an exercise price of $14.09 per share and an expiration date in June 2036.

How many Relay Therapeutics (RLAY) shares are covered by Claire Mazumdar’s new options?

The grant covers 32,947 underlying shares of Relay Therapeutics common stock. These are stock options, not currently owned shares, and they give Mazumdar the right to buy the shares at a fixed exercise price of $14.09 per share in the future.

When do Claire Mazumdar’s Relay Therapeutics (RLAY) stock options vest?

The options vest in full based on time and the next shareholder meeting. Vesting occurs on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders following that grant date.

What is the exercise price and expiration date of the Relay Therapeutics (RLAY) options granted to Claire Mazumdar?

The options have a $14.09 exercise price and expire on June 8, 2036. This means she can buy up to 32,947 shares at $14.09 per share any time after vesting and before the June 8, 2036 expiration.

Is Claire Mazumdar’s Form 4 transaction in Relay Therapeutics (RLAY) an open-market buy or a grant?

The transaction is a grant, not an open-market purchase. The Form 4 uses transaction code “A” for a grant, award, or other acquisition, indicating a compensation-related stock option award rather than a discretionary market trade by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar Claire

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.09	06/09/2026		A		32,947		(1)	06/08/2036	Common Stock	32,947	$0	32,947	D

Explanation of Responses:

1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)